Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis.
$547.09+0.85%
报价 2026-11-06
市值
$138.67B
EV
$113.41B
PE (TTM)
29.0x
预期 PE (FY2026)
30.0x
52 周区间距高点 -2.1%
$421.03$558.88
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
爆发潜力
2026-11-07不在筛选范围：industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| VRTXVertex Pharmaceuticals Incorporated | $138.67B | +0.8% | +8.8% | 86.3% | 29.0x | 23.5x | 43.4x | |
| MDTMedtronic plc | $130.22B | -2.9% | +8.0% | 62% | 24.2x | 14.8x | – | |
| BMYBristol-Myers Squibb Company PFD CONV 2 | $127.02B | -1.6% | -1.5% | 67.7% | 16.5x | 10.5x | 9.9x | |
| SYKStryker Corporation | $124.02B | -2.8% | +8.8% | 63.5% | 39.2x | 24.7x | 28.9x | |
| MCKMcKesson Corporation | $123.68B | -1.0% | +6.6% | 3.6% | 24.9x | 17.6x | 12.2x | |
| SNYSanofi | $113.26B | +0.3% | – | 71.7% | 8.9x | 9.7x | – | |
| CVSCVS Health Corporation | $107.24B | +3.1% | +1.7% | 13.8% | 51.2x | 17.8x | 13.7x | |
| HCAHCA Healthcare, Inc. | $103.4B | -2.5% | +4.5% | 14.9% | 16.4x | 9.7x | 17.3x | |
| GSKGSK plc | $102.02B | -0.2% | – | 72.5% | 13.7x | 7.8x | – | |
| 同行中位数 | – | – | +5.5% | 62.7% | 20.4x | 12.7x | 13.7x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。